- Home
- CASI vs CLNN Comparison
CASI vs CLNN Comparison
Compare CASI & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- CLNN
- Stock Information
- Founded
- CASI 1991
- CLNN 2012
- Country
- CASI China
- CLNN United States
- Employees
- CASI N/A
- CLNN N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- CLNN Health Care
- Exchange
- CASI Nasdaq
- CLNN Nasdaq
- Market Cap
- CASI 20.5M
- CLNN 23.1M
- IPO Year
- CASI 1996
- CLNN N/A
- Fundamental
- Price
- CASI $2.36
- CLNN $5.66
- Analyst Decision
- CASI Strong Buy
- CLNN Strong Buy
- Analyst Count
- CASI 1
- CLNN 5
- Target Price
- CASI $4.00
- CLNN $33.00
- AVG Volume (30 Days)
- CASI 3.7M
- CLNN 106.4K
- Earning Date
- CASI 09-02-2025
- CLNN 08-14-2025
- Dividend Yield
- CASI N/A
- CLNN N/A
- EPS Growth
- CASI N/A
- CLNN N/A
- EPS
- CASI N/A
- CLNN N/A
- Revenue
- CASI $31,368,000.00
- CLNN $286,000.00
- Revenue This Year
- CASI N/A
- CLNN N/A
- Revenue Next Year
- CASI N/A
- CLNN $1,753.57
- P/E Ratio
- CASI N/A
- CLNN N/A
- Revenue Growth
- CASI 8.39
- CLNN N/A
- 52 Week Low
- CASI $1.09
- CLNN $2.28
- 52 Week High
- CASI $7.67
- CLNN $6.90
- Technical
- Relative Strength Index (RSI)
- CASI 64.70
- CLNN 77.55
- Support Level
- CASI $1.95
- CLNN $3.50
- Resistance Level
- CASI $3.09
- CLNN $5.70
- Average True Range (ATR)
- CASI 0.34
- CLNN 0.41
- MACD
- CASI 0.07
- CLNN 0.23
- Stochastic Oscillator
- CASI 55.21
- CLNN 97.74
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.